Long-Term Safety and Efficacy of Subcutaneous Cladribine Used in Increased Dosage in Patients with Relapsing Multiple Sclerosis: 20-Year Observational Study

Long-Term Safety and Efficacy of Subcutaneous Cladribine Used in Increased Dosage in Patients with Relapsing Multiple Sclerosis: 20-Year Observational Study

Cladribine is currently registered as a 10-milligram tablet formulation with a fixed cumulative dosage of 3.5 mg/kg over 2 years. It is important to investigate if an increased dosage may lead to further clinical stability with preserved safety. This study used an off-label subcutaneous (s.c.) formu...

Full description

Saved in:
Bibliographic Details
Main Authors: Konrad Rejdak, Adriana Zasybska, Aleksandra Pietruczuk, Dariusz Baranowski, Sebastian Szklener, Magda Kaczmarek, Zbigniew Stelmasiak
Format: article
Language:EN
Published: MDPI AG 2021
Subjects:
subcutaneous cladribine
relapsing multiple sclerosis
long-term efficacy
safety
Medicine
R
Online Access:https://doaj.org/article/5ce9cff1154f4c1fa32b9b618856822a
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items